COMPARISON OF CLASS-SPARING TO 3-DRUG REGIMENS FOR INITIAL HIV THERAPY

初始 HIV 治疗中类保留疗法与 3 种药物疗法的比较

• 批准号: 7379351
• 负责人: Jeffrey Thomas Schouten
• 金额: $ 0.46万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7379351
• 关键词: COMPARISON; CLASS; SPARING; DRUG; REGIMENS

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a phase III, randomized, 3-arm, open-label study comparing the effectiveness of the following three regimens for the initial treatment of HIV infection: a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen (efavirenz (EFV) + stavudine-extended release (d4T XR) [or zidovuidine (ZDV) or tenofovir (TDF)] + epivir (3TC), a (ritonavir) RTV-enhanced protease inhibitor (PI)-based regimen (lopinavir LPV/RTV + d4T XR [or ZDV or TDF] + 3TC), and, a nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen (EFV + LPV/RTV). This study will enroll 660 HIV-1-infected, ARV (antiretroviral)-naive male and female subjects >18 years of age.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。这是一项III期、随机、3组、开放标签研究，比较了以下三种方案用于HIV感染初始治疗的有效性：基于非核苷类逆转录酶抑制剂（NNRTI）的治疗方案（依法韦仑（EFV）+司他夫定-缓释（d4 T XR）[或齐多夫定（ZDV）或替诺福韦（TDF）] + epivir（3 TC），基于（利托那韦）RTV增强蛋白酶抑制剂（PI）的方案（洛匹那韦LPV/RTV + d4 T XR [或ZDV或TDF] +3 TC）和核苷逆转录酶抑制剂（NRTI）保留方案（EFV + LPV/RTV）。本研究将招募660名HIV-1感染的ARV（抗逆转录病毒）初治男性和女性受试者，年龄>18岁。